Miners et al. [21] conclude that the extrapolation of in vitro-in vivo studies indicates that the inhibition of UGT1A1 significantly contributes to hyperbilirubinemia observed in patients treated with sorafenib. Here, UGT1A1 is linked to Hyperbilirubinemia.